NCO-700
NCO-700 is a dual cathepsin B and calcium-activated neutral protease (CANP) inhibitor with IC50 values of 0.8 and 46 μM, respectively. NCO-700 reduces the degradation of myocardial fibrin by inhibiting protease activity. NCO-700 also has inhibitory effects on hormone-independent tumor cells, such as prostate cancer cells, and induces apoptosis. NCO-700 can be used to study myocardial ischemia and refractory hormone-independent tumors.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 84518-80-9
- Formule: C26H39N3O8
- Masse moléculaire:521.60
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Cathepsin
More
Activité biologique
NCO-700 (7 days) inhibits HS-578T, PC-3, DU-145, MCF-7, LNCaP and T47D cells proliferation with IC50s of 7.5, 10, 11.5, 72 and >100 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
NCO-700 (10-100 mg/kg, i.p., once daily for 5 days) demonstrates significant anti-tumor activity in xenograft models of prostate cancer and breast cancer in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:
-
Dosage:20 and 40 mg/kg (total dose)
-
Administration:Intraperitoneal injection (i.p.), 4 administrations of medication
-
Result:Reduced the infarcted area by 11.5% and 22.3% at 20 and 40 mg/kg in rabbit model.
Significantly inhibited the degradation of myofibrillar proteins induced by ischemia in dog model.
-
Animal Model:Xenograft models of prostate cancer and breast cancer established in Balb/C mice[2]
-
Dosage:10, 20 and 40 mg/kg (prostate cancer) and 10, 50 and 100 mg/kg (breast cancer)
-
Administration:Intraperitoneal injection (i.p.), once daily for 5 days
-
Result:Significantly slowed down the growth rate of the tumor.
Induced cell apoptosis in cancer cells removed from animals.
Chemical Information
-
CAS No. 84518-80-9
-
Masse moléculaire 521.60
-
Formule C26H39N3O8
-
SMILES
O=C(N1CCN(CC2=C(C(OC)=C(OC)C=C2)OC)CC1)[C@H](CC(C)C)NC([C@H]3[C@H](C(OCC)=O)O3)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Toyo-oka T, et al. Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease. Jpn Heart J. 1982 Sep;23(5):829-34. [Content Brief]
[2]. Eilon GF, et al. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents. Cancer Chemother Pharmacol. 2000;45(3):183-91. [Content Brief]
[3]. Sashida H, Abiko Y. Inhibition with NCO-700, a protease inhibitor, of degradation of cardiac myofibrillar proteins during ischemia in dogs. Biochem Pharmacol. 1985 Nov 1;34(21):3875-80. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NCO-700 Related Classifications
HY-106058 Related Classifications
Powered by Bioz